<SEC-DOCUMENT>0001558370-24-005767.txt : 20240425
<SEC-HEADER>0001558370-24-005767.hdr.sgml : 20240425
<ACCEPTANCE-DATETIME>20240425161020
ACCESSION NUMBER:		0001558370-24-005767
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240425
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240425
DATE AS OF CHANGE:		20240425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		24876370

	BUSINESS ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20240425x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.6.2.5 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 4/25/2024 7:27:05 PM -->
<!-- iXBRL Library version: 1.0.8826.24652 -->
<!-- iXBRL Service Job ID: d6656258-ff8a-47ef-9e1f-15b248c800c2 -->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20240425" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityCentralIndexKey" id="Tc_Y3vRkB7A6keG7qmzYE4Zyg_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:AmendmentFlag" id="Tc_zagpBHD06U2h906zKfmE6A_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tmb-20240425.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3fc39a1a_887a_483a_8c79_81c09bc11603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:DocumentType" id="Narr_kcld3i3NgUuk6cpjTDsTjQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:DocumentPeriodEndDate" id="Narr_2BfZMzFpn0WzwR1e8z9LxA"><b style="font-size:9pt;font-weight:bold;">April 25, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityRegistrantName" id="Narr_uhZqqyQuXkqn9JY3GvT8EA"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_RqyHO5WwekmDrlbbn9eeVA_2_0"></a><a id="Tc_VpCS9PGU2E6rnIYY44slXw_2_2"></a><a id="Tc_zx6hfWQbmkqrcdKb7Mlwyw_2_4"></a><a id="Tc_dcJS0YD2tE26LANfMV0W_w_3_0"></a><a id="Tc_vVstYHHdLkGlnewWaVDJSQ_3_2"></a><a id="Tc_XrVvwo-F90OGWpqdxthCJw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityIncorporationStateCountryCode" id="Tc_MwJYBfu95EeY3F62nbBqXg_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityFileNumber" id="Tc_ArrMnu7PO06C3QkmBw7RJw_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityTaxIdentificationNumber" id="Tc_Ef_PyfnjhkqnO90bL69tjw_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_6kalNaxkKEaouQfjoeEBUQ_2_0"></a><a id="Tc_JLhK7QbtxU6X6uInkyTnWA_3_0"></a><a id="Tc_BiV6ahTQhUqBWbA3vt_MYA_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityAddressAddressLine1" id="Tc_lfNy4nmdx0qharjWm2iq9Q_1_0"><b style="font-size:9pt;font-weight:bold;">500 Warren Corporate Center Drive</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityAddressCityOrTown" id="Narr_t1CjCLf5Lk6emLdCqtqM4Q"><b style="font-size:9pt;font-weight:bold;">Warren</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityAddressStateOrProvince" id="Narr_UhN8-a-sr0e2CMGYtQ_alw"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityAddressPostalZipCode" id="Tc_ZdrZd_KlmUuqvNpN1Lvbpw_2_3"><b style="font-size:9pt;font-weight:bold;">07059</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:CityAreaCode" id="Narr_iqDfMBoTokOuZt0RSh76rg"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:LocalPhoneNumber" id="Narr_V5B2sIiOkU6baW_i6IHR2Q"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w" name="dei:EntityAddressAddressLine1" id="Narr_sUfBZmvjjkqIyTr6BqkMRA"><b style="font-size:9pt;font-weight:bold;">100 Corporate Court</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w" name="dei:EntityAddressCityOrTown" id="Narr_ju-1F5POE0WvUJuLwuq0CQ"><b style="font-size:9pt;font-weight:bold;">South Plainfield</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w" name="dei:EntityAddressStateOrProvince" id="Narr_dGx2yvXwlkanq1mBXjK09Q"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w" name="dei:EntityAddressPostalZipCode" id="Narr_OFdnvXKKZUKh4fgCk5l3zg"><b style="font-size:9pt;font-weight:bold;">07080</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:WrittenCommunications" id="Narr_z-kKRFSRgE2S_1c1OWwgFA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:SolicitingMaterial" id="Narr_W7m349i-M02hJjeNht88FA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:PreCommencementTenderOffer" id="Narr_IwijIFauwUe0P9bAy7nfug"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:PreCommencementIssuerTenderOffer" id="Narr_cSBBpwB3Jky1TfFs0gRJHA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_VHrdclCXjka7SJrruqzcOQ_1_0"></a><a id="Tc_-PPWWnU9VE-lzMdztOo8Ow_1_2"></a><a id="Tc_aTAENR1GA0ae5GAUpMcOlA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:Security12bTitle" id="Tc_LM-9R1-msEyqKzwXDCLUvw_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:TradingSymbol" id="Tc_vUZLapyl9ECvv1GuiNRdFQ_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:SecurityExchangeName" id="Tc_z07V0f8keEmk9ycNnnlC0Q_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w" name="dei:EntityEmergingGrowthCompany" id="Narr_pzHGe3-YGUSomsbi_N7lEA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_d7eab7b2_b496_431f_b9e0_9c0fd5303292"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Item 2.02. Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On April 25, 2024, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March&#160;31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit&#160;99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d302d167_1063_4403_a40b_8d5d10d227b7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Item 7.01. Regulation FD Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The Company will host a conference call on April 25, 2024 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter ended March 31, 2024, as well as other corporate highlights and updates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Directions on how to access the conference call are included in the press release furnished as Exhibit 99.1 hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_48095604_0281_4f13_826d_d5402f0cd453"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20240425xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated April 25, 2024 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7a9a790c_ca0a_427d_8646_fdd7e62f3db0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: April 25, 2024</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20240425xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 4/25/2024 07:27:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Therapeutics Provides Corporate Update and </b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Reports First Quarter 2024 Financial Results</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Strong revenue performance across product portfolio &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; Submitted MAA for sepiapterin and BLA for Upstaza &#8211;</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">&#8211; On target to achieve remaining 2024 clinical and regulatory milestones, </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">including global submissions for sepiapterin &#8211; </i><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">WARREN, N.J., April 25, 2024</b><font style="font-family:'Arial','Helvetica','sans-serif';"> &#8211; PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2024.&#160;&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="color:#212121;font-family:'Arial','Helvetica','sans-serif';">&#8220;We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter,&#8221; said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. &#8220;We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin.&quot;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Corporate Updates:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First quarter 2024 total revenue of $210 million</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First quarter 2024 revenue for the DMD franchise was $161 million</font></td></tr></table><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Translarna&#8482; (ataluren) net product revenue was $104 million, driven by</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> new patients in existing geographies and continued geographic expansion.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-left:22.5pt;margin-top:0pt;padding-left:18pt;text-indent:-18pt;"><font style="display:inline-block;font-family:'Courier New';font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">o</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Emflaza</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> (deflazacort) net product revenue was $57 million, resulting from </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">new patient starts and high compliance. </font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Key Clinical and Regulatory Milestones:</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC submitted an MAA to the EMA for sepiapterin for the treatment of PKU in March 2024. The company expects to submit an NDA to the FDA for sepiapterin no later than the third quarter of 2024 and to complete regulatory submissions in Japan and Brazil in 2024. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC submitted a BLA to the FDA for Upstaza&#8482; for the treatment of AADC deficiency in March 2024.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on FDA feedback, PTC plans to resubmit the NDA for Translarna for the treatment of nmDMD in mid-2024.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on FDA feedback, PTC plans to submit an NDA for vatiquinone for the treatment of FA in late 2024.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The interim data update for the PIVOT-HD trial of PTC518 for HD patients remains on schedule for the second quarter of 2024. This update will include 12-month data on the initial group of subjects for whom data were reported in June 2023, as well as 12-week data on a larger number of stage 2 and stage 3 HD patients.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC expects to report topline data for the CardinALS trial of utreloxastat for ALS in the fourth quarter of 2024. </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">First Quarter 2024 Financial Highlights:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenues were $210.1 million for the first quarter of 2024, compared to $220.4 million for the first quarter of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Total revenue includes net product revenue across the commercial portfolio of $177.6 million for the first quarter of 2024, compared to $187.6 million for the first quarter of 2023. Total revenue also </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">includes collaboration, royalty, and manufacturing revenue of $32.5 million in the first quarter of 2024, compared to $32.8 million for the first quarter of 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Translarna net product revenues were $103.6 million for the first quarter of 2024, compared to $115.1 million for the first quarter of 2023, </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">driven by</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> new patients in existing geographies and continued geographic expansion. The decrease was due to the timing of bulk patient orders.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Emflaza net product revenues were $57.5 million for the first quarter of 2024, compared to $54.6 million for the first quarter of 2023. These results were driven by new patient starts and high compliance.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Roche reported Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;vertical-align:top;">&#174;</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2024 year-to-date sales of approximately $400 million, resulting in royalty revenue of $31.2 million to PTC for the first quarter of 2024, as compared to $30.8 million for the first quarter of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on U.S. GAAP (Generally Accepted Accounting Principles), GAAP R&amp;D expenses were $116.1 million for the first quarter of 2024, compared to $195.1 million for the first quarter of 2023. The decrease in research and development expenses reflects strategic portfolio prioritization as the Company continues to focus its resources on its differentiated, high-potential R&amp;D programs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP R&amp;D expenses were $107.2 million for the first quarter of 2024, excluding $9.0 million in non-cash, stock-based compensation expense, compared to $179.8 million for the first quarter of 2023, excluding $15.3 million in non-cash, stock-based compensation expense.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">GAAP SG&amp;A expenses were $73.3 million for the first quarter of 2024, compared to $86.9 million for the first quarter of 2023. The decrease in selling, general and administrative expenses reflects lower employee costs as a result of the reduction in workforce in 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Non-GAAP SG&amp;A expenses were $63.9 million for the first quarter of 2024, excluding $9.4 million in non-cash, stock-based compensation expense, compared to $73.4 million for the first quarter of 2023, excluding $13.5 million in non-cash, stock-based compensation expense. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Change in the fair value of deferred and contingent consideration was a gain of $0.1 million for the first quarter of 2024, compared to a loss of $2.4 million for the first quarter of 2023. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The net loss was $91.6 million for the first quarter of 2024, compared to a net loss of $139.0 million for the first quarter of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash, cash equivalents, and marketable securities was $884.8 million on March 31, 2024, compared to $876.7 million on December 31, 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Shares issued and outstanding as of March 31, 2024, were 76,653,960.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">PTC Reaffirms Full Year 2024 Financial Guidance:</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates total revenues for full year 2024 to be between $600 million and $680 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates GAAP R&amp;D and SG&amp;A expense for full year 2024 to be between $740 and $835 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates Non-GAAP R&amp;D and SG&amp;A expense for full year 2024 to be between $660 and $755 million, including expected R&amp;D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&amp;D operating expense.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Non-GAAP Financial Measures:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">In this press release, the financial results of PTC are provided in accordance with GAAP and using certain non-GAAP financial measures. In particular, the non-GAAP R&amp;D and SG&amp;A expense financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management&#39;s opinion, these non-GAAP financial measures are useful to investors and other users of PTC&#39;s financial </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">statements by providing greater transparency into the historical and projected operating performance of PTC and the company&#39;s future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:5pt;line-height:1.19;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 146.15pt 8pt 133.9pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-size:11pt;"><br></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Consolidated Statements of Operations</b><font style="font-size:11pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';">(In thousands, except share and per share data)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:92.3%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:12.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:middle;width:38.87%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Three Months Ended March 31,&#160;</b></p></td><td style="vertical-align:bottom;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1.5pt solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2024</b></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Revenues:</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net product revenue</font></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 177,604</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 187,557</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Collaboration revenue</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 6</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Royalty revenue</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 31,154</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 30,831</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Manufacturing revenue</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:15.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">1,</font><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">360</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,988</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total revenues</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 210,118</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 220,382</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Operating expenses:</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Cost of product sales, excluding amortization of acquired intangible assets</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 14,740</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 14,144</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Amortization of acquired intangible asset</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 51,530</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 39,415</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Research and development (1)</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 116,129</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 195,124</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Selling, general and administrative (2)</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 73,272</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 86,914</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Change in the fair value of deferred and contingent consideration</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;"> </font><u style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</u><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">100</font><u style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)</u></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 2,400</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Total operating expenses</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 255,571</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 337,997</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Loss from operations</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (45,453)</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (117,615)</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Interest expense, net</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (40,834)</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (27,331)</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Other income, net</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 1,591</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 9,956</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Loss before income tax expense</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (84,696)</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (134,990)</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Income tax expense</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (6,880)</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (3,969)</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net loss attributable to common stockholders</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">(91,576)</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (138,959)</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Weighted-average shares outstanding:</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Basic and diluted (in shares)</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 76,496,127</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 73,729,284</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> (1.20)</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">(1.88)</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(1) Research and development reconciliation</b></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP research and development</font></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 116,129</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 195,124</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 8,967</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 15,314</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP research and development</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 107,162</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 179,810</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:7.2pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:7pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</b></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">GAAP selling, general and administrative</font></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 73,272</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 86,914</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">Less: share-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 9,411</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 13,501</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;font-weight:bold;">Non-GAAP selling, general and administrative </b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:15.61%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 63,861</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;">$</font></p></td><td style="vertical-align:middle;width:12.77%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8.5pt;white-space:pre-wrap;"> 73,413</font></p></td><td style="vertical-align:middle;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:57.71%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:19.49%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:2.73%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.65%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.4%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8.5pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0.5pt 146.45pt 8pt 134.05pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-size:11pt;"><br></font><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Summary Consolidated Balance Sheets</b><font style="font-size:11pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';">(in thousands, except share data)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:99.51%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.9%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:16.9%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2023</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Cash, cash equivalents and marketable securities</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">884,813</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:1px solid #000000;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">876,739</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total assets</b></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1,789,629</b></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1,895,698</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total debt</font></p></td><td style="vertical-align:middle;width:4.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:12.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 284,512</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:12.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 284,213</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total deferred revenue</font></p></td><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> -</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 801</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total liability for sale of future royalties</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 1,838,933</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1,814,097</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,683,545</b></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">2,714,253</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:12.88%;border-top:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total stockholders&#39; deficit (76,653,960 and 75,708,889 common shares issued and outstanding at March 31, 2024, and December 31, 2023, respectively)</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(893,916)</font></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(818,555)</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:62.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Total liabilities and stockholders&#39; deficit</b></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1,789,629</b></p></td><td style="vertical-align:middle;width:3.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:4.02%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:12.88%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">1,895,698</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.4pt 0pt 8pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;background:#ffffff;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">PTC Therapeutics, Inc.</b><font style="font-size:12pt;"><br></font><b style="font-weight:bold;">Reconciliation of GAAP Milestone Payments Full Year 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;background:#ffffff;margin:0pt 0pt 0pt 6pt;">(in millions)</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100.96%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.76%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:21.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:26.19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PTC Therapeutics, Inc.</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reconciliation of GAAP </b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Milestone Payments </b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:26.19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Full Year 2024</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:26.19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">(in millions)</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:26.19%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Projected GAAP R&amp;D Expense Related Milestone Payments</font></p></td><td style="vertical-align:middle;width:4.76%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:21.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 65</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Projected GAAP Contingent Consideration Payable Related Milestone Payments</font></p></td><td style="vertical-align:middle;width:4.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:21.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 25</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:73.8%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Total Projected GAAP Milestone Payments</font></p></td><td style="vertical-align:middle;width:4.76%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:21.42%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">90</b></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0.4pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">PTC Therapeutics, Inc.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.28;text-align:center;margin:0.4pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2024 R&amp;D and SG&amp;A Expense</b><font style="font-size:11pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';">(In millions)</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:99.51%;"><tr style="height:0.75pt;"><td style="vertical-align:middle;width:53.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:6pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.67%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low End of Range</b></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.67%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High End of Range</b></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Projected GAAP R&amp;D and SG&amp;A Expense</font></p></td><td style="vertical-align:middle;width:9.01%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.66%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 740</font></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.01%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.66%;border-top:1.5pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 835</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Less: projected non-cash, stock-based compensation expense</font></p></td><td colspan="2" style="vertical-align:middle;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 80</font></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:middle;width:18.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 80</font></p></td></tr><tr style="height:15pt;"><td style="vertical-align:middle;width:53.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense </b></p></td><td style="vertical-align:middle;width:9.01%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.66%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 660</font></p></td><td style="vertical-align:middle;width:9.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:9.01%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">$</font></p></td><td style="vertical-align:middle;width:9.66%;border-bottom:2.25pt double #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> 755</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0.4pt 52.9pt 0pt 60.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Acronyms:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">AADC: Aromatic l-Amino Acid Decarboxylase</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">ALS: Amyotrophic Lateral Sclerosis</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BLA: Biologics License Application</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">CHF: Confoederatio Helvetica Francs (Swiss francs)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">DMD: Duchenne Muscular Dystrophy</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">EMA: European Medicines Agency</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FA: Friedreich Ataxia</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">FDA: U.S. Food and Drug Administration</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GAAP: Generally Accepted Accounting Principles</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">HD: Huntington&#8217;s Disease</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">MAA: Marketing Authorization Application</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">NDA: New Drug Application</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">nmDMD: Nonsense Mutation Duchenne Muscular Dystrophy</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PKU: Phenylketonuria</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">R&amp;D: Research and Development</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SG&amp;A: Selling, General, and Administrative</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Today&#39;s Conference Call and Webcast Reminder: </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">To access the call by phone, please </font><font style="font-family:'Arial','Helvetica','sans-serif';">click here</font><font style="font-family:'Arial','Helvetica','sans-serif';"> to register and yo</font>u will b<font style="font-family:'Arial','Helvetica','sans-serif';">e provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at </font><font style="font-family:'Arial','Helvetica','sans-serif';">https://ir.ptcbio.com/events-presentations</font><font style="font-family:'Arial','Helvetica','sans-serif';">. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for 30 days following the call.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC Therapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC&#39;s ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company&#39;s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at </font><font style="font-family:'Arial','Helvetica','sans-serif';">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';"> and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">For More Information:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Investors:</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Kylie O&#39;Keefe</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 300-0691</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">kokeefe@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Media:</b><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">Jeanine Clemente</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">+1 (908) 912-9406</font><font style="font-size:11pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">jclemente@ptcbio.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Forward-Looking Statements:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading &quot;PTC Reaffirms Full Year 2024 Revenue Guidance&quot;, including with respect to (i) 2024 total revenue guidance, (ii) 2024 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance and (iii) 2024 acquisition related milestone payment guidance, and statements regarding: the future expectations, plans and prospects for PTC, including with respect to the expected timing of clinical trials and studies, availability of data, regulatory submissions and responses, commercialization and other matters with respect to its products and product candidates; PTC&#39;s strategy, future operations, future financial position, future revenues, projected costs; the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce; and the objectives of management. Other forward-looking statements may be identified by the words, &quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; PTC&#39;s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in Brazil, Russia, the European Economic Area (EEA) and other regions, including whether the European Commission adopts the negative opinion from the Committee for Medicinal Products for Human Use (CHMP) for the conditional marketing authorization for Translarna in the EEA; PTC&#39;s ability to use the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, and from its international drug registry study to support a marketing approval for Translarna for the treatment of nmDMD in the United States; whether investigators agree with PTC&#39;s interpretation of the results of clinical trials and the totality of clinical data from our trials in Translarna; expectations with respect to Upstaza, including any regulatory submissions and potential approvals, commercialization, manufacturing capabilities, the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; expectations with respect to the commercialization of Evrysdi under our SMA collaboration; expectations with respect to the commercialization of Tegsedi and Waylivra; the timing of and actual expenses incurred in connection with the discontinuation of PTC&#39;s preclinical and early research programs in gene therapy and reductions in workforce, which may be in different periods and may be materially higher than estimated; the savings that may result from the discontinuation of PTC&#39;s strategic pipeline prioritization and reductions in workforce, which may be materially less than </font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:9pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">expected; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; the potential financial impact and benefits of PTC&#39;s leased biologics manufacturing facility; PTC&#39;s ability to satisfy its obligations under the terms of its lease agreements, including for its leased biologics manufacturing facility; the sufficiency of PTC&#39;s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, Upstaza, Evrysdi, Tegsedi or Waylivra.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:100%;"><tr style="height:15pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt -5.75pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt -5.75pt 0pt 0pt;"><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tmb-20240425.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/25/2024 7:27:11 PM-->
<!--Modified on: 4/25/2024 7:27:11 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20240425" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20240425" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20240425_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20240425_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20240425_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>tmb-20240425_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/25/2024 7:27:11 PM-->
<!--Modified on: 4/25/2024 7:27:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tmb-20240425.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20240425.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_FormerAddressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_WrittenCommunications" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_SolicitingMaterial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_PreCommencementTenderOffer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>tmb-20240425_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/25/2024 7:27:11 PM-->
<!--Modified on: 4/25/2024 7:27:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_FormerAddressMember" xlink:to="dei_FormerAddressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_FormerAddressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Address [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_FormerAddressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>tmb-20240425_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.6.2.5 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/25/2024 7:27:11 PM-->
<!--Modified on: 4/25/2024 7:27:11 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20240425.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressesTable_638496700311180994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesTable_638496700311180994" xlink:to="dei_EntityAddressesAddressTypeAxis_638496700311180994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_638496700311180994" xlink:to="dei_AddressTypeDomain_638496700311180994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_FormerAddressMember" xlink:label="dei_FormerAddressMember_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_638496700311180994" xlink:to="dei_FormerAddressMember_638496700311180994" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesTable_638496700311180994" xlink:to="dei_EntityAddressesLineItems_638496700311180994" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_DocumentType_638496700311180994" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638496700311180994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_DocumentPeriodEndDate_638496700311180994" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638496700311191069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityFileNumber_638496700311191069" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638496700311191069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityRegistrantName_638496700311191069" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638496700311191069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityIncorporationStateCountryCode_638496700311191069" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638496700311191069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityTaxIdentificationNumber_638496700311191069" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638496700311191069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityAddressAddressLine1_638496700311191069" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638496700311251026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityAddressCityOrTown_638496700311251026" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638496700311251026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityAddressStateOrProvince_638496700311251026" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638496700311251026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityAddressPostalZipCode_638496700311251026" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638496700311251026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_CityAreaCode_638496700311251026" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638496700311251026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_LocalPhoneNumber_638496700311251026" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638496700311251026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_WrittenCommunications_638496700311251026" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_SolicitingMaterial_638496700311260986" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_PreCommencementTenderOffer_638496700311260986" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_PreCommencementIssuerTenderOffer_638496700311260986" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_Security12bTitle_638496700311260986" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_TradingSymbol_638496700311260986" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_SecurityExchangeName_638496700311260986" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638496700311260986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityEmergingGrowthCompany_638496700311260986" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638496700311270981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_EntityCentralIndexKey_638496700311270981" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638496700311270981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesLineItems_638496700311180994" xlink:to="dei_AmendmentFlag_638496700311270981" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140375247143280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Warren Corporate Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former address</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MK>1:1]^5[#>Z3\RZK2817X.0>]6'-:J*SU[%A9%I_JEI)8V1<7ZZY0SJ /L
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 2H&96)>*NQS
M    $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y
M 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/
M:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O
M.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_
M'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !*
M@9E8'#AEZC\!   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^
M0!-0BU1$N)0^D*H6E8K[DG6(Q3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q'
M]>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1
M:T/9=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLD
MO,3 QFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!
M+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<
M)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:
M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ 2H&96 =!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !*@9E8
M2IMZ0>\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !*@9E8F5R<(Q &  "<)P  $P              @ '-
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $J!F5BHZ3 RS 0
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M2P$"% ,4    " !*@9E8)!Z;HJT   #X 0  &@              @ %!$@
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !*@9E899!Y
MDAD!  #/ P  $P              @ $F$P  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"  !P%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20240425x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20240425.xsd</File>
    <File>tmb-20240425_def.xml</File>
    <File>tmb-20240425_lab.xml</File>
    <File>tmb-20240425_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20240425x8k.htm">tmb-20240425x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20240425x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20240425",
   "dts": {
    "schema": {
     "local": [
      "tmb-20240425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20240425_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20240425_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20240425_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20240425x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 28,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 26
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20240425x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20240425x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "terseLabel": "Former address",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-24-005767-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-005767-xbrl.zip
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M#FM2+'+*"W?&]B?K]U=WQCIU>/W9]_U_4$L#!!0    ( $J!F5@PG2VBG1<
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M=(;;\MQAT*9K+LE]%P8Q+2>Z[6(JV87/H/M7'=W=<"2AS[1B[BM+>$DJ0U_
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M9\=FES+M9 3==04S<<];572X='#(!4':?2Q M%I8<S$]O7@]\_(;K:9R!X>
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M*"E07;?MM-SFIDBURLDJIPV4TV]X)PQ3<>:/.21\*469AU) >%;6N55 1U=
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M7?A<10&=]/0+<UTW</3@W&:C:[30!)@IH"LT.M-2Q0-7^>*Q=2JVH+_^QZN
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M<<]!%S73P;N-\VJMN7V*;C8E]_GFBMR,F*012V#\RB&_A5Y5Y]Z6(T,3&X>
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M^&.6<+@@"B""%?T4VNHG"O<A*,+ &_(64T;IQ^BY\-!/,'[AI-$*A[ T4.6
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M4$L! A0#%     @ 2H&96#B_\X$7!0  PS$  !0              ( !FQ
M '1M8BTR,#(T,#0R-5]P<F4N>&UL4$L! A0#%     @ 2H&96#"=+:*=%P
M3[<  !,              ( !Y!4  '1M8BTR,#(T,#0R-7@X:RYH=&U02P$"
M% ,4    " !*@9E80'F@( @O   -MP( %P              @ &R+0  =&UB
J+3(P,C0P-#(U>&5X.3ED,2YH=&U02P4&      8 !@"* 0  [UP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tmb-20240425x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20240425.xsd" xlink:type="simple"/>
    <context id="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <context id="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_Y3vRkB7A6keG7qmzYE4Zyg_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_zagpBHD06U2h906zKfmE6A_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_kcld3i3NgUuk6cpjTDsTjQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_2BfZMzFpn0WzwR1e8z9LxA">2024-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_uhZqqyQuXkqn9JY3GvT8EA">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_MwJYBfu95EeY3F62nbBqXg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_ArrMnu7PO06C3QkmBw7RJw_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_Ef_PyfnjhkqnO90bL69tjw_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_lfNy4nmdx0qharjWm2iq9Q_1_0">500 Warren Corporate Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_t1CjCLf5Lk6emLdCqtqM4Q">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_UhN8-a-sr0e2CMGYtQ_alw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_ZdrZd_KlmUuqvNpN1Lvbpw_2_3">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_iqDfMBoTokOuZt0RSh76rg">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_V5B2sIiOkU6baW_i6IHR2Q">222-7000</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w"
      id="Narr_sUfBZmvjjkqIyTr6BqkMRA">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w"
      id="Narr_ju-1F5POE0WvUJuLwuq0CQ">South Plainfield</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w"
      id="Narr_dGx2yvXwlkanq1mBXjK09Q">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_4_25_2024_To_4_25_2024_dei_EntityAddressesAddressTypeAxis_dei_FormerAddressMember_7jtPIRTndkCDZtoHgZez6w"
      id="Narr_OFdnvXKKZUKh4fgCk5l3zg">07080</dei:EntityAddressPostalZipCode>
    <dei:WrittenCommunications
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_z-kKRFSRgE2S_1c1OWwgFA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_W7m349i-M02hJjeNht88FA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_IwijIFauwUe0P9bAy7nfug">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_cSBBpwB3Jky1TfFs0gRJHA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_LM-9R1-msEyqKzwXDCLUvw_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_vUZLapyl9ECvv1GuiNRdFQ_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Tc_z07V0f8keEmk9ycNnnlC0Q_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_4_25_2024_To_4_25_2024_cQaEuhp3Skiby7MZMMgB5w"
      id="Narr_pzHGe3-YGUSomsbi_N7lEA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
